Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials
Open Access
- 1 April 2020
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 31 (4), 525-531
- https://doi.org/10.1016/j.annonc.2020.01.006
Abstract
No abstract availableKeywords
Funding Information
- F. Hoffmann-La Roche Ltd
- F Hoffmann-La Roche
- Genentech
This publication has 24 references indexed in Scilit:
- Proton pump inhibitors alter the composition of the gut microbiotaGut, 2015
- Proton pump inhibitors affect the gut microbiomeGut, 2015
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience, 2015
- PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 2014
- The Intestinal Microbiota Modulates the Anticancer Immune Effects of CyclophosphamideScience, 2013
- Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor MicroenvironmentScience, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerThe New England Journal of Medicine, 2012
- Risk of Community-Acquired Pneumonia and Use of Gastric Acid–Suppressive DrugsJAMA, 2004